Rapid direct method for monitoring antibiotics in a mouse model of bacterial biofilm infection

Antimicrobial Agents and Chemotherapy

Volumn 47, Issue 10, 2003, Pages 3130-3137

  Kadurugamuwa, Jagath L ^a   Sin, Lin V ^a   Yu, Jun ^a   Francis, Kevin P ^a   Kimura, Richard ^a   Purchio, Tony ^a   Contag, Pamela R ^a  

^a Xenogen Corporation   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; ANTIINFECTIVE AGENT; CIPROFLOXACIN; RIFAMPICIN; TOBRAMYCIN;

ANIMAL; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL CHROMOSOME; BACTERIAL COUNT; BACTERIAL INFECTION; BACTERIAL PHENOMENA AND FUNCTIONS; BIOFILM; BIOLUMINESCENCE; CATHETERIZATION; COLONY FORMING UNIT; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG EFFECT; DRUG EFFICACY; DRUG MONITORING; GENETICS; GROWTH, DEVELOPMENT AND AGING; IN VITRO STUDY; IN VIVO STUDY; METHODOLOGY; MICROBIOLOGY; MOUSE; NONHUMAN; OPERON; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL INFECTIONS; BIOFILMS; CATHETERIZATION; CHEMILUMINESCENT MEASUREMENTS; CIPROFLOXACIN; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG MONITORING; MICE; RIFAMPIN; STAPHYLOCOCCUS AUREUS; TOBRAMYCIN;

EID: 0141891106     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.47.10.3130-3137.2003     Document Type: Article

References (47)

1. Bayer, A. S., and K. Lam. 1985. Efficacy of vancomycin plus rifampin in experimental aortic-valve endocarditis due to methicillin-resistant Staphylococcus aureus: in vitro-in vivo correlations. J. Infect. Dis. 151:157-165.
2. Blaser, J., P. Vergeres, A. F. Widmer, and W. Zimmerli. 1995. In vivo verification of in vitro model of antibiotic treatment of device-related infection. Antimicrob. Agents Chemother. 39:1134-1139.
3. Brown, M. R., and P. Williams. 1985. The influence of environment on envelope properties affecting survival of bacteria in infections. Annu. Rev. Microbiol. 39:527-556.
4. Ceri, H., M. E. Olson, C. Stremick, R. R. Read, D. Morck, and A. Buret. 1999. The Calgary biofilm device: new technology for rapid determination of antibiotic susceptibilities of bacterial biofilms. J. Clin. Microbiol. 37:1771-1776.
5. Contag, C. H., P. R. Contag, J. I. Mullins, S. D. Spilman, D. K. Stevenson, and D. A. Benaron. 1995. Photonic detection of bacterial pathogens in living hosts. Mol. Microbiol. 18:593-603.
6. Contag, C. H., S. D. Spilman, P. R. Contag, M. Oshiro, B. Eames, P. Dennery, D. K. Stevenson, and D. A. Benaron. 1997. Visualizing gene expression in living mammals using a bioluminescent reporter. Photochem. Photobiol. 66:523-531.
7. Contag, P. R., I. N. Olomu, D. K. Stevenson, and C. H. Contag. 1998. Bioluminescent indicators in living mammals. Nat. Med. 4:245-247.
8. Costerton, J. W., P. S. Stewart, and E. P. Greenberg. 1999. Bacterial biofilms: a common cause of persistent infections. Science 284:1318-1322.
9. Davies, D. 2003. Understanding biofilm resistance to antibacterial agents. Nat. Rev. Drug Discov. 2:114-122.
10. Francis, K. P., D. Joh, C. Bellinger-Kawahara, M. J. Hawkinson, T. F. Purchio, and P. R. Contag. 2000. Monitoring bioluminescent Staphylococcus aureus infections in living mice using a novel luxABCDE construct. Infect. Immun. 68:3594-3600.
11. Francis, K. P., J. Yu, C. Bellinger-Kawahara, D. Joh, M. J. Hawkinson, G. Xiao, T. F. Purchio, M. G. Caparon, M. Lipsitch, and P. R. Contag. 2001. Visualizing pneumococcal infections in the lungs of live mice using bioluminescent Streptococcus pneumoniae transformed with a novel gram-positive lux transposon. Infect. Immun. 69:3350-3358.
12. Gagnon, R. F., A. D. Harris, J. Prentis, and G. K. Richards. 1989. The effects of heparin on rifampin activity against Staphylococcus epidermidis biofilms. Adv. Perit. Dial. 5:138-142.
13. Gagnon, R. F., G. K. Richards, and R. Subang. 1992. Experimental Staphylococcus epidermidis implant infection in the mouse. Kinetics of rifampin and vancomycin action. Am. Soc. Artif. Intern. Organs J. 38:M596-M599.
14. Gracia, E., A. Fernandez, P. Conchello, J. L. Alabart, M. Perez, and B. Amorena. 1999. In vitro development of Staphylococcus aureus biofilms using slime-producing variants and ATP-bioluminescence for automated bacterial quantification. Luminescence 14:23-31.
15. Gracia, E., A. Lacleriga, M. Monzon, J. Leiva, C. Oteiza, and B. Amorena. 1998. Application of a rat osteomyelitis model to compare in vivo and in vitro the antibiotic efficacy against bacteria with high capacity to form biofilms. J. Surg. Res. 79:146-153.
16. Hickey, M. J., T. M. Arain, R. M. Shawar, D. J. Humble, M. H. Langhorne, J. N. Morgenroth, and C. K. Stover. 1996. Luciferase in vivo expression technology: use of recombinant mycobacterial reporter strains to evaluate antimycobacterial activity in mice. Antimicrob. Agents Chemother. 40:400-407.
17. Huang, C., F. Yu, G. McFeters, and P. Stewart. 1995. Nonuniform spatial patterns of respiratory activity within biofilms during disinfection. Appl. Environ. Microbiol. 61:2252-2256.
18. Kadurugamuwa, J. L., A. J. Clarke, and T. J. Beveridge. 1993. Surface action of gentamicin on Pseudomonas aeruginosa. J. Bacteriol. 175:5798-5805.
19. Kadurugamuwa, J. L., L. Sin, E. Albert, J. Yu, K. Francis, M. DeBoer, M. Rubin, C. Bellinger-Kawahara, T. R. Parr, Jr., and P. R. Contag. 2003. Direct continuous method for monitoring biofilm infection in a mouse model. Infect. Immun. 71:882-890.
20. Lee, S. H., and A. Camilli. 2000. Novel approaches to monitor bacterial gene expression in infected tissue and host. Curr. Opin. Microbiol. 3:97-101.
21. Lewis, K. 2001. Riddle of biofilm resistance. Antimicrob. Agents Chemother. 45:999-1007.
22. Loimaranta, V., J. Tenovuo, L. Koivisto, and M. Karp. 1998. Generation of bioluminescent Streptococcus mutans and its usage in rapid analysis of the efficacy of antimicrobial compounds. Antimicrob. Agents Chemother. 42:1906-1910.
23. Lucet, J. C., M. Herrmann, P. Rohner, R. Auckenthaler, F. A. Waldvogel, and D. P. Lew. 1990. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. Antimicrob. Agents Chemother. 34:2312-2317.
24. Marines, F. 2000. On-line monitoring of growth of Escherichia coli in batch cultures by bioluminescence. Appl. Microbiol. Biotechnol. 53:536-541.
25. Mermel, L. A., B. M. Farr, R. J. Sherertz, I. I. Raad, N. O'Grady, J. S. Harris, and D. E. Craven. 2001. Guidelines for the management of intravascular catheter-related infections. Clin. Infect. Dis. 32:1249-1272.
26. Montero, A., J. Ariza, X. Corbella, A. Domenech, C. Cabellos, J. Ayats, F. Tubau, C. Ardanuy, and F. Gudiol. 2002. Efficacy of colistin versus β-lactams, aminoglycosides, and rifampin as monotherapy in a mouse model of pneumonia caused by multiresistant Acinetobacter baumannii. Antimicrob. Agents Chemother. 46:1946-1952.
27. Monzon, M., F. Garcia-Alvarez, A. Lacleriga, E. Gracia, J. Leiva, C. Oteiza, and B. Amorena. 2001. A simple infection model using pre-colonized implants to reproduce rat chronic Staphylococcus aureus osteomyelitis and study antibiotic treatment. J. Orthoped. Res. 19:820-826.
28. Mouton, J. W., M. L. van Ogtrop, D. Andes, and W. A. Craig. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob. Agents Chemother. 43:2473-2478.
29. National Committee for Clinical Laboratory Standards. 1997. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7-A4. National Committee for Clinical Laboratory Standards, Wayne, Pa.
30. Neu, H. C. 1992. The crisis in antibiotic resistance. Science 257:1064-1073.
31. Norden, C. W., and E. Keleti. 1980. Treatment of experimental staphylococcal osteomyelitis with rifampin and trimethoprim, alone and in combination. Antimicrob. Agents Chemother. 17:591-594.
32. O'Toole, G. A. 2002. Microbiology: a resistance switch. Nature 416:695-696.
33. Parveen, A., G. Smith, V. Salisbury, and S. M. Nelson. 2001. Biofilm culture of Pseudomonas aeruginosa expressing lux genes as a model to study susceptibility to antimicrobials. FEMS Microbiol. Lett. 199:115-118.
34. Rocchetta, H. L., C. J. Boylan, J. W. Foley, P. W. Iversen, D. L. LeTourneau, C. L. McMillian, P. R. Contag, D. E. Jenkins, and T. R. Parr, Jr. 2001. Validation of a noninvasive, real-time imaging technology using bioluminescent Escherichia coli in the neutropenic mouse thigh model of infection. Antimicrob. Agents Chemother 45:129-137.
35. Rupp, M. E., J. S. Ulphani, P. D. Fey, K. Bartscht, and D. Mack. 1999. Characterization of the importance of polysaccharide intercellular adhesin/hemagglutinin of Staphylococcus epidermidis in the pathogenesis of biomaterial-based infection in a mouse foreign body infection model. Infect. Immun. 67:2627-2632.
36. Salisbury, V., A. Pfoestl, H. Wiesinger-Mayr, R. Lewis, K. E. Bowker, and A. P. MacGowan. 1999. Use of a clinical Escherichia coli isolate expressing lux genes to study the antimicrobial pharmacodynamics of moxifloxacin. J. Antimicrob. Chemother. 43:829-832.
37. Schwank, S., Z. Rajacic, W. Zimmerli, and J. Blaser. 1998. Impact of bacterial biofilm formation on in vitro and in vivo activities of antibiotics. Antimicrob. Agents Chemother. 42:895-898.
38. Simon, L., C. Fremaux, Y. Cenatiempo, and J. M. Berjeaud. 2001. Luminescent method for the detection of antibacterial activities. Appl. Microbiol. Biotechnol. 57:757-763.
39. Svensson, E., H. Hanberger, M. Nilsson, and L. E. Nilsson. 1997. Factors affecting development of rifampicin resistance in biofilm-producing Staphylococcus epidermidis. J. Antimicrob. Chemother. 39:817-820.
40. Tenhami, M., K. Hakkila, and M. Karp. 2001. Measurement of effects of antibiotics in bioluminescent Staphylococcus aureus RN4220. Antimicrob. Agents Chemother. 45:3456-3461.
41. Ulitzur, S. 1986. Determination of antibiotic activities with the aid of luminous bacteria. Methods Enzymol. 133:275-284.
42. Van Wijngaerden, E., W. E. Peetermans, J. Vandersmissen, S. Van Lierde, H. Bobbaers, and J. Van Eldere. 1999. Foreign body infection: a new rat model for prophylaxis and treatment. J. Antimicrob. Chemother. 44:669-674.
43. Vogelman, B., S. Gudmundsson, J. Turnidge, J. Leggett, and W. A. Craig. 1988. In vivo postantibiotic effect in a thigh infection in neutropenic mice. J. Infect. Dis. 157:287-298.
44. Widmer, A. F., R. Frei, Z. Rajacic, and W. Zimmerli. 1990. Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections. J. Infect. Dis. 162:96-102.
45. Zak, O., W. M. Scheld, and M. A. Sande. 1983. Rifampin in experimental endocarditis due to Staphylococcus aureus in rabbits. Rev. Infect. Dis. 5(Suppl. 3):S481-S490.
46. Zimmerli, W., F. A. Waldvogel, P. Vaudaux, and U. E. Nydegger. 1982. Pathogenesis of foreign body infection: description and characteristics of an animal model. J. Infect. Dis. 146:487-497.
47. Zimmerli, W., A. F. Widmer, M. Blatter, R. Frei, P. E. Ochsner, et al. 1998. Role of rifampin for treatment of orthopedic implant-related staphylococcal infections: a randomized controlled trial. JAMA 279:1537-1541.